A Study of TQ-B3525 on Tolerance and Pharmacokinetics

A Phase I Study of TQ-B3525 on Tolerance and Pharmacokinetics

NCT03510767•Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Summary

To study the pharmacokinetic characteristics of TQ-B3525 in the human body, recommend a reasonable regimen for subsequent research.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

•Relapsed or refractory lymphoma or advanced solid tumor that diagnosed Pathologically or cytologically diagnosed
•ECOG PS≤1
•Adequate blood cell counts, kidney function and liver function
•Patients should participate in the study voluntarily and sign informed consent

•Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history
•Hypertension (systolic BP ≥150 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by one medication
•Hepatitis B virus patients with active replication (DNA\> 500 cps / mL), hepatitis C

Locations (1)

People's Hospital of Tianjin

Tianjin, Tianjin Municipality, China

Key Dates

Start Date

June 20, 2018

Primary Completion Date

August 15, 2022

Completion Date

August 1, 2024

Last Updated

April 14, 2023

Enrollment

ESTIMATED participants

Conditions

Relapsed or Refractory Lymphoma or Advanced Cancer

Interventions

TQ-B3525

DRUG

Contacts

Huaqing Wang, doctor

CONTACT